UNSPSC 51293003: Amitriptylinoxide

This classification denotes an antidepressant agent with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TYR2U59WMA, chemically known as 10,11-dihydro-n,n-dimethyl-5h-dibenzo(a,d)cycloheptene-delta(sup 5,gamma)-propylamine n-oxide but generally known as amitriptylinoxide, which bears US NIH Compound Identifier 20313. European Medicines Agency schedules Amitriptylinoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05463MIG.

UNSPSC 51293003 Amitriptylinoxide is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity does not center on amitriptylinoxide itself. Instead, the code appears in solicitations for broader pharmaceutical procurement programs—including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. State and local governments use this code family to procure pharmaceutical inventory, medical supplies, and pharmacy benefit program support through health departments, cooperative purchasing consortia, and state HHS agencies. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local facilities across multiple jurisdictions including Oregon). Work solicited ranges from fixed-quantity annual purchases of specific medications to exploratory requests for information on direct-to-manufacturer contracting models and comprehensive generic pharmaceutical catalogs meeting FDA manufacturing and supply-chain security standards.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the multistate cooperative MMCAP, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026 and contract effectiveness targeted for July 1, 2026; this procurement requires manufacturers to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. Vendors bidding under this code typically must hold workers' compensation and commercial general liability insurance, certify drug-free workplace status, and comply with E-Verify requirements and federal environmental regulations when funding involves FEMA or other federal sources.